Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Launch of Innovation Division & Expansion of Business Throughout Europe

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Venn has announced the launch of InnoVenn.

Venn Life Sciences has announced the launch of InnoVenn, Venn’s new innovation division set up to focus on co-development opportunities, particularly in the medical device arena.

The goal of InnoVenn is to accelerate the commercialization of life science products in the later stages of development.

InnoVenn’s first co-development initiative will be a joint venture with two Irish biomedical companies, Cellulac Limited and Biopharmed West Limited, developing the next generation of biodegradable human implants, to replace the widespread use of titanium in orthopaedic surgery.

Biodegradable implants degrade at the same rate as the matching tissue which eliminates the need for further surgery to remove and replace metal alternatives.

Venn will provide clinical research services at a subsidized rate for the project for a future carry within the ventures.

The launch of InnoVenn comes at a time which has seen Venn expanding its operations throughout Europe. Following on from the establishment of Venn Russia in February 2013, the Company also announces that it has recently opened an additional office in the UK, extending its reach throughout Europe.

The new UK office has seen Venn augment its Clinical Resourcing business with the appointment of Stewart Hulse as Vice President Resourcing.

Stewart has over 15 years of clinical research and recruitment experience and has placed business in over 19 countries worldwide.

Venn currently provides resourcing solutions across Europe exclusively in the areas of clinical research across all positions.

Commenting, Venn CEO, Tony Richardson, said: “This joint venture instantly provides access to medical device technologies that fit well within our strategic vision. With the expansion of our coverage and services throughout Europe we are able to offer our clients valuable on the ground support in the all too often difficult area of managing clinical trial across European borders.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Venn Expands in Europe with Two Acquisitions
Company acquires German CRO CRM clinical trials and Medevol Clinical Services in the UK.
Tuesday, December 10, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!